Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.90 USD
+0.02 (2.51%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Lineage Cell Therapeutics, Inc. [LCTX]
Reports for Purchase
Showing records 61 - 80 ( 99 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Continues to Impress at ARVO; FDA Talks Planned for 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VAC Platform Delivers First Partnership; We Expect More to Come; Important OpRegen Update Coming at ARVO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Hitting All the Right Notes in Interim Analysis of Dry AMD Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Busy Catalyst Year with OpRegen Leading the Charge; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: $57M in Cash; Funds Operations to 2023
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Investor Day Underscores OPC1 Potential; Readies for Regulatory Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Next OPC1 Improvement in Sight with License Agreement Seeking to Improve Cell Delivery
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Thesis Keeps Improving Investor Vision; Pictures Speak Volumes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen''s Future Continues to Brighten; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Important Inflection Points Over Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Lineage Cashing a Big Check; No Monday Morning Blues Here
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Things Are Crankin'' on Multiple Levels; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Restarts Dosing Post COVID Restrictions; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Experts Weigh in on Great Observation; Target Increased to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Only One, Thus Far, But Sure Makes Sense; First Known Report of Retinal Tissue Regeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Feedback Highlights Promise of OpRegen in Dry AMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J